Erstellt von fchar99
Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics Inc.
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
1,12 €
-1,45 %
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for AKBA provided by MarketBeat
Neueste Beiträge
henryashford in FuelCell Energy Inc. diskutieren